NVAX Stock Plunged: Here's What Happened

The Situation

Novavax Inc (NASDAQ: NVAX) shares – a biotech company dedicated to developing and commercializing vaccines for infectious diseases – plunged on Thursday after it proposed convertible senior notes. As of 12:00 PM ET, Novavax shares dropped by 19.85%.

The Explanation

Novavax Inc officially went public on Dec 5, 1995, reaching an all-time high of $319.93 on Feb 8, 2021. NVAX is now down 90.34% year-to-date at $13.876 as of press time. So far, the stock is down 83.28% overall.

The company announced a proposed offering of convertible senior notes due in 2027 with an aggregated principal amount of $125 million. The company expects to grant initial purchasers a 30-day option to purchase an additional $18.75 million worth of notes.

The company said they may use the proceeds from the notes for general purposes, including the repayment or repurchase of a portion of the $325 million in outstanding principal owned to their previous convertible senior unsecured notes that are due on Feb 1, 2023.

See the $NVAX chart performance here.

The Effect

Novavax Inc stocks dropped upon its announced convertible senior notes. The investors' reactions happened despite other announcements of the company's big plans, like making COVID shots in Canada. Since investors can't know for sure how the convertible senior notes will perform, it is more important to focus on Novavax's business.

See full $NVAX flow at: https://unusualwhales.com/stock/NVAX/flow-overview

tastytrade logo+
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.